Physician profile
Deborah C Murphy
NPI 1205830783
$13,400.52
in general payments reported to CMS, 2019-2025
36 companies · $2,531 in 2025
The $2,531 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,584 · 2022: $2,086 · 2023: $3,285 · 2024: $2,914 · 2025: $2,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,730.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,739.43 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,463.55 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $1,159.17 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $990.92 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $863.96 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $788.90 | 2021-2025 | |
| Lundbeck LLC | $663.96 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $663.06 | 2021-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $622.56 | 2021-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $455.73 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $399.95 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $390.15 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $290.99 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $272.44 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $255.64 | 2021-2025 | Aplenzin, Wellbutrin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $249.00 | 2023 | Nuplazid |
| Almatica Pharma LLC | $212.65 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $211.80 | 2023-2024 | Jornay Pm |
| Mylan INC. | $204.94 | 2022-2023 | Yupelri |
| Corium, LLC | $190.69 | 2022-2024 | Azstarys |
| Neos Therapeutics, Lp | $189.64 | 2021-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $181.64 | 2025 | Jornay Pm |
| Bioxcel Therapeutics, INC. | $138.17 | 2023 | Igalmi |
| Eisai INC. | $122.00 | 2021 | |
| Merck Sharp & Dohme LLC | $121.25 | 2021-2023 | Belsomra |
| Noven Pharmaceuticals, INC. | $95.63 | 2024 | Xelstrym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $83.93 | 2023 | Abilify Maintena |
| Jazz Pharmaceuticals INC. | $74.24 | 2021-2022 | |
| Noven Therapeutics, LLC | $71.62 | 2023-2025 | Xelstrym, Secuado |
| Avanir Pharmaceuticals, INC. | $63.84 | 2021-2022 | |
| Indivior INC. | $47.60 | 2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $35.39 | 2025 | Cobenfy |
| Tris Pharma INC | $30.85 | 2023 | Dyanavel Xr |
| Biogen, INC. | $25.02 | 2024 | |
| Adlon Therapeutics L.P. | $16.45 | 2021 | |
| Vertical Pharmaceuticals, LLC | $13.76 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.